Engineering the Future of Precision Delivery and Targeted Protein Degradation
NanoMedSyn develops AMFA glycoligands to specifically target the mannose 6-phosphate receptor (M6PR) to enable the precise intracellular delivery of therapeutics and the selective lysosomal addressing of disease‑driving antigens for degradation.
Our technology creates new mechanisms of action for major therapeutic classes by exploiting endogenous M6PR‑mediated trafficking:
- Therapeutic antibodies engineered with AMFA become first‑in‑class degraders capable of directing soluble or membrane pathogenic antigens to lysosomes for degradation
- Therapeutic nanoparticles modified with AMFA bind to the M6PR and are internalized into extra‑hepatic tissues, expanding the reach of RNA, enzymes, and other biologics.
- Enzyme conjugated with AMFA improves the lysosomal delivery of enzyme replacement therapy for rare metabolic diseases.
By unlocking controlled intracellular routing, we open new frontiers in drug discovery that were once considered unreachable.
Learn more about our advanced AMFA technology targeting M6PR to treat a wide range of pathologies